You are here

  • Home
  • Archive
  • Volume 11, Issue 8
  • A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design

Citation Tools

Article menu
XML
Urology
Protocol
A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Freedland SJ, De Giorgi U, Gleave M, et al
A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design
BMJ Open 2021;11:e046588. doi: 10.1136/bmjopen-2020-046588